The Centre for the Commercialization of Antibodies and Biologics welcomes new CEO
The Centre for the Commercialization of Antibodies and Biologics (CCAB) Board of Directors is pleased to announce the appointment of Mr. Robert Verhagen as the organization’s new Chief Executive Officer, effective November 1, 2017.
Mr. Verhagen brings to CCAB more than 20 years of business and leadership experience in the pharmaceutical and diagnostics fields. Most notably, he was the CEO at Helix Biopharma where he led the reorganization of the company, raising over $30 million and advancing its NSCLC candidate through early stage clinical trials.
Additionally, Mr. Verhagen sits on the Portfolio Development Committee for InnovateCalgary, providing diligence and advice to early-stage companies involved in all areas of new technology development, from life sciences to cleantech. He has held executive or senior management roles at Spectral Medical Inc., MDS Inc., and founded INH Technologies Inc. Mr. Verhagen has raised over $45 million for various companies and had led the licensing or acquisition of six therapeutics.
As CCAB’s new CEO, Mr. Verhagen will provide his strategic direction to position CCAB as a leader in the commercialization of academic discoveries in the biologics field and in the advancement of this biotech sector in Canada.